SCHEMBL7910338

SCHEMBL7910338

O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(C(=O)N[C@H](CO)c2ccccc2)(c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.47
SLC6A7 Q99884 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HSD11B1 P28845 1/20 0.44
MAPK1 P28482 2/20 0.43
MAPK13 O15264 1/20 0.43
ROCK2 O75116 1/20 0.43
RPS6KA5 O75582 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
PRKCG P05129 1/20 0.43
CDK1 P06493 1/20 0.43
PRKACA P17612 1/20 0.43
RPS6KB1 P23443 1/20 0.43
CDK2 P24941 1/20 0.43
AKT1 P31749 1/20 0.43
AKT2 P31751 1/20 0.43
CLK2 P49760 1/20 0.43
GSK3A P49840 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378790 1.00 TACR1 (0.47) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL7900391 0.95 TACR1 (0.43) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL378802 0.89 SLC6A9 (0.47) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL7908350 0.89 HSD11B1 (0.46) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL7907192 0.85 SLC6A7 (0.47) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL378786 0.84 MEN1 (0.46) SLC6A7KMT2AMEN1HSD11B1MAPK1
SCHEMBL3714839 0.84 NPC1 (0.49) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL7908348 0.83 HSD11B1 (0.48) SLC6A7KMT2AMEN1HSD11B1FASN
SCHEMBL437707 0.83 HSD11B1 (0.41) TACR1SLC6A7KMT2AMEN1HSD11B1
SCHEMBL378834 0.82 TACR1 (0.48) TACR1SLC6A7KMT2AMEN1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TACR1 19/4885SLC6A7 105/4885KMT2A 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.